Revisiting Pulmonary Sclerosing Pneumocytoma

Clin Pract. 2024 Jul 22;14(4):1440-1450. doi: 10.3390/clinpract14040116.

Abstract

Pulmonary sclerosing pneumocytoma (PSP) is a quite rare tumor outside Eastern countries. This rarity, together with a wide histological appearance, makes its correct identification a diagnostic challenge for pathologists under the microscope. Historically, PSP was considered a vascular-derived neoplasm (sclerosing hemangioma), but its immunohistochemical profile clearly supports its epithelial origin. No specific molecular fingerprint has been detected so far. This short narrative revisits the clinical, histological, immunohistochemical, and molecular aspects of this tumor, paying special attention to some controversial points still not well clarified, i.e., clinical aggressiveness and metastatic spread, multifocality, the supposed development of sarcomatoid change in a subset of cases, and tumor associations with lung adenocarcinoma and/or well-differentiated neuroendocrine hyperplasia/tumors. The specific diagnostic difficulties on fine-needle aspiration cytology/biopsy and perioperative frozen sections are also highlighted. Finally, a teaching case of tumor concurrence of lung adenocarcinoma, neuroendocrine lesions, and PSP, paradigmatic of tumor association in this context, is also presented.

Keywords: differential diagnosis; immunohistochemistry; lung adenocarcinoma; pulmonary neuroendocrine hyperplasia; pulmonary sclerosing pneumocytoma; well-differentiated neuroendocrine tumor.

Publication types

  • Review

Grants and funding

This research received no external funding.